Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02343952
Title Consolidation Pembrolizumab (MK-3475), Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Nasser Hanna, M.D.
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Comprehensive Cancer Center Duarte California 91010 United States Details
Fort Wayne Oncology & Hematology, Inc. Fort Wayne Indiana 46845 United States Details
IU Health Goshen Hospital Goshen Indiana 46527 United States Details
Indiana University Melvin and Bren Simon Cancer Center Indianapolis Indiana 46202 United States Details
IU Health Central Indiana Cancer Centers Indianapolis Indiana 46219 United States Details
Community Regional Cancer Care Indianapolis Indiana 49256 United States Details
IU Health Arnett Cancer Center Lafayette Indiana 47904 United States Details
Horizon Oncology Research, Inc. Lafayette Indiana 47905 United States Details
IU Health at Ball Memorial Hospital Muncie Indiana 47303 United States Details
Oncology Hematology Associates of SW Indiana Newburgh Indiana 47630 United States Details
Northern Indiana Cancer Research Consortium South Bend Indiana 46601 United States Details
University of Louisville, James Graham Brown Cancer Center Louisville Kentucky 40202 United States Details
Nebraska Cancer Specialists Omaha Nebraska 68114 United States Details
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903 United States Details
University of Virginia Health System Charlottesville Virginia 22908 United States Details
*Shaded cells indicate that there was no data available from for the field